Technical Analysis for NVO - Novo Nordisk A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | -0.29% | |
| Multiple of Ten Bearish | Other | -0.29% | |
| Gapped Up | Strength | -0.29% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.41% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.41% | |
| Bollinger Band Squeeze | Range Contraction | 0.41% | |
| Inside Day | Range Contraction | 0.41% | |
| 20 DMA Support | Bullish | 0.81% | |
| Bollinger Band Squeeze | Range Contraction | 0.81% | |
| BB Squeeze Started | Range Contraction | 0.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 31 minutes ago |
| 20 DMA Support | about 5 hours ago |
| 2x Volume Pace | about 6 hours ago |
| 1.5x Volume Pace | about 6 hours ago |
| Down 1 ATR | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 02/01/2023
Novo Nordisk A/S Description
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diabetes Pharmaceutical Products Inflammation Insulin Endocrine System Obesity Hormones Peptide Hormones Growth Hormone Glucagon Like Peptide 1 Diabetes Care Growth Hormone Therapy Haemophilia Pharmaceuticals Segment Anti Diabetic Drugs Hormone Therapy Related Delivery Systems
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 144.78 |
| 52 Week Low | 94.75 |
| Average Volume | 1,354,359 |
| 200-Day Moving Average | 114.01 |
| 50-Day Moving Average | 130.83 |
| 20-Day Moving Average | 137.62 |
| 10-Day Moving Average | 139.51 |
| Average True Range | 2.48 |
| RSI | 60.63 |
| ADX | 38.07 |
| +DI | 37.80 |
| -DI | 18.18 |
| Chandelier Exit (Long, 3 ATRs) | 137.35 |
| Chandelier Exit (Short, 3 ATRs) | 137.53 |
| Upper Bollinger Bands | 142.46 |
| Lower Bollinger Band | 132.78 |
| Percent B (%b) | 0.65 |
| BandWidth | 7.03 |
| MACD Line | 2.34 |
| MACD Signal Line | 2.81 |
| MACD Histogram | -0.4696 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 141.97 | ||||
| Resistance 3 (R3) | 142.22 | 141.49 | 141.49 | ||
| Resistance 2 (R2) | 141.49 | 140.75 | 141.37 | 141.32 | |
| Resistance 1 (R1) | 140.28 | 140.29 | 139.92 | 140.03 | 141.16 |
| Pivot Point | 139.55 | 139.55 | 139.37 | 139.43 | 139.55 |
| Support 1 (S1) | 138.34 | 138.81 | 137.98 | 138.09 | 136.96 |
| Support 2 (S2) | 137.61 | 138.35 | 137.49 | 136.80 | |
| Support 3 (S3) | 136.40 | 137.61 | 136.64 | ||
| Support 4 (S4) | 136.15 |
